5月27日，派格生物医药-B盘中下跌15.99%，报9.29港元/股，成交额4687.47万港元。
消息面上，派格生物医药-B于去年5月27日在港交所挂牌上市，今日恰逢上市满一周年，IPO前股东所持股份禁售期全面到期，大量低成本筹码集中解禁。据公开信息，除A轮及创始人外，其余股东持股成本约在8-11港元区间，当前股价已接近解禁股东成本线，叠加此前已有多家机构股东陆续离场，市场对集中抛售压力的担忧加剧。公司去年全年亏损2.08亿元，基本面尚未实现盈利，进一步放大了解禁冲击。
派格生物医药是一家深耕慢病代谢领域的生物科技公司，核心产品为接近商业化阶段的长效GLP-1受体激动剂PB-119，主要用于治疗2型糖尿病及肥胖症等代谢疾病。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.